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Finally, as with any emerging technology it is important that 
we understand its clinical ramifications: How is the use of the 
MC method likely to impact patient outcomes? Methods 
toward clearly addressing this question are fraught with 
challenges. We will summarize the approaches being used in 
evaluating the clinical impact of MC-based photon dose 
calculations and will discuss the associated issues.  
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In 1916 Dr. C. Thurston Holland addressed the role of the 
professionals that we now know as RTTs in the following 
terms:  “The place of these people…..is merely that of 
assistants.  They work directly under medical control, accept 
no responsibilities of any kind, and merely do as they are 
told” 
Radiotherapy practice is unrecognizable in 2015 when 
compared to the time when this statement was made.  
 Almost a century later RTTs have largely become recognized 
as professionals who contribute significantly to the activities 
carried out in our radiotherapy departments.   However 
achieving professional recognition has been a long and 
contentious road that despite gathering momentum in recent 
decades and has a long way to go.    
Being a part of the radiotherapy team in the current 
environment is stimulating, exciting and rewarding and the 
opportunities post 2020 are immense.  In this rapidly 
changing environment professional practice must be 
constantly adapted to keep, not only abreast, but ahead of 
the scientific and technological developments.   RTTs must 
review and reconsider the way they practice and be prepared 
to move from the traditional to the innovative.  RTTs are 
rapidly becoming the drivers of their own practice, have met 
the challenges and adapted readily to the spectrum of 
technology now in routine use and must continue to do so.     
What does the future hold?  Adaptive planning will be 
routine, biological treatment planning will be coming into 
practice, new molecular approaches will be coming on 
stream all leading to individualized treatment for patients.  
Choice of treatment plan based on image evaluation will be 
normal practice for the RTT and will bring about a changing 
relationship with their patient and other members of the 
team.   For RTTs the challenges of 2020 are immense and we 
must also position ourselves to be ready to meet these 
challenges and provide care to our patients consistent with 
the ESTRO Vision Statement: “challenges of individualised 
patient care will be achieved by integrating new clinical and 
preclinical evidence from biology, molecular/functional 
imaging and the use of new systemic agents together with 
the delivery of high precision radiation therapy in a safety 
aware environment” 
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At present, standard RT volume is the whole prostate gland, 
as is the case of radical prostatectomy. This is due to 2 
factors: 1) multifocal intraprostatic spread of prostate cancer 
and 2) impossibility to identify tumor foci on the standard RT 
planning imaging modality (computer tomography, [CT]). 
However, the whole organ one-dose level RT is rarely used in 
solid tumors. Localized approach, i.e. RT to tumor site only 
or to the whole organ followed by boost to tumor site is 
common. Several reports have demonstrated that 
 dominant/biggest intraprostatic lesion (DIL) is the major site 
of recurrence after prostate cancer RT. Introduction of new 
imaging technologies (Positron Emission Tomography [PET], 
Single PET [SPECT], extended transrectal ultrasound [TRUS]-
biopsies, Doppler ultrasound and multiparametric magnetic 
resonance [mpMRI]) has allowed to identify DIL. According to 
the international consensus, mpMRI including T2-weighted 
imaging (T2WI), diffusion weighted imaging (DWI) and 
dynamic contrast enhanced (DCE) images represents the 
optimal current prostate imaging1. This opens 2 new 
scenarios: 1) boosting DIL concomitantly/sequentially to the 
whole prostate RT and 2) partial prostate irradiation (PPI) 
i.e. primary focal RT. 
As far as DIL boosting is concerned, up till now 11 series (833 
pts) have been published2. Both external beam RT (EBRT) and 
brachytherapy (BRT) have been used as boost, with 8 Gy (3-
35Gy) or 150% (130-155%) boost/whole prostate dose, 
respectively. DIL boost has been studied mainly in the 
conventional fractionation (IMRT + simultaneous integrated 
boost [SIB]), and only recently DIL SIB for extreme 
hypofractionation has been evaluated. 5 planning studies (3 
 EBRT and 2 BRT, 65 pts) have been published, comparing 
different RT techniques (see fig. as example) and different 
dose schemes (128% mean ratio boost/whole prostate dose, 
range 110-150%). 2 studies on patient series have been 
published (76 pts) using EBRT or high-dose-rate (HDR) BRT 
(112% mean ratio between boost/whole prostate dose, range 
108-116%). Delivering DIL SIB in extreme hypofractionation 
appears feasible but should be approached with caution. 
Clinical value of DIL dose escalation is unknown. Ongoing 
trials like FLAME, HEIGHT, DELINEATE, NCT01409473 and 
NCT01913717 will contribute to further assessment of 
boosting DIL. 
Primary focal therapy has been explored for 20 years now 
and more than 2000 patients have been treated3 (mainly with 
cryosurgery, high-intensity ultrasound [HIFU], photodynamic 
